Stryker Biotech reached a settlement with the US Attorney's Office for the District of Massachusetts to resolve a 2009 federal grand jury indictment, according to a Stryker news release.
The company pled guilty to one misdemeanor charge and paid a fine of $15 million. As a result, the department of justice dismissed 13 felony charges against the company. The company was charged with marketing unapproved products for human bone growth, according to Bloomberg Businessweek news report.
Stryker's misbrand may have led surgeons to combine the company's OP-1 and OP-1 Putty with bone filler Calstrux, which could have adverse events.
Related Articles on Orthopedic Devices:
Zyga Technology Names Jim Bullock President & CEO
Zimmer Acquires Synvasive Technology
VG Innovations Releases Spine Device for Low Back Pain
Stryker's misbrand may have led surgeons to combine the company's OP-1 and OP-1 Putty with bone filler Calstrux, which could have adverse events.
Related Articles on Orthopedic Devices:
Zyga Technology Names Jim Bullock President & CEO
Zimmer Acquires Synvasive Technology
VG Innovations Releases Spine Device for Low Back Pain